As part of the settlement, the underlying litigation will be dismissed, the Hyderabad-headquartered drugmaker said.
As part of the settlement, the underlying litigation will be dismissed, the Hyderabad-headquartered drugmaker said.
Pharma major Dr. Reddy’s Laboratories has tied up with British drugmaker Indivir, which is settling a patent lawsuit related to the opioid dependence treatment drug Suboxone.
Dr Reddy’s said on Friday that the company has entered into agreements with Indiwear Inc., Indiwear UK Ltd and Acquasive Therapeutics Inc., after which it will receive a total payment of $72 million by March 31, 2024.
This agreement settles all claims between parties related to Dr. Reddy’s generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages; Indivior’s and Aquestive’s allegation of patent infringement and the company’s antitrust counterclaims.
As part of the settlement, the underlying litigation will be dismissed, the Hyderabad-headquartered drugmaker said.